NITI Aayog is reviewing regulatory hurdles to reduce India's heavy reliance on imported medical and dental equipment. The body is targeting the 10-15% cost disadvantage faced by domestic firms and long approval timelines. This initiative is significant for investors as it could change the operational environment for listed medical device companies and affect how they compete with global imports.
NITI Aayog has started a formal review of the medical and dental device sector to help India move toward being a larger manufacturing hub. The government body is examining ways to reduce the country’s high dependence on imports, which currently account for a significant portion of the total medical equipment used in the country. The review includes officials from the Department of Pharmaceuticals, the Indian Council of Medical Research, and experts from engineering institutions like IIT Delhi and IIT Mumbai.
The core issue being addressed is the difficulty faced by local manufacturers. Industry groups, including the Association of Indian Medical Device Industry, have noted that domestic companies struggle with a 10-15% cost disadvantage compared to imported products. This extra cost comes from higher energy expenses, complex logistics, and limited access to initial capital for business setup.
Another major concern for the industry is the time taken for regulatory approvals. Data shared during these discussions indicates that the time required to set up facilities and gain necessary permits has increased from about 18 months in the past to nearly four years currently. This administrative delay makes it difficult for local firms to scale up production and compete with established global players who import their products into India.
To solve these problems, the government is considering a dedicated legislative framework for medical devices. The goal is to move away from using broader pharmaceutical regulations, which the industry feels are not suitable for the unique needs of medical device technology. By simplifying the approval process and improving testing facilities, the government hopes to lower the barrier for domestic companies to enter the market.
For investors, the potential changes could have a direct impact on companies involved in manufacturing medical equipment in India. Reduced regulatory friction and better infrastructure could potentially improve profit margins and operational efficiency for these firms. However, success will depend on the government's ability to implement these policies effectively without compromising on the quality and safety standards of the medical devices produced.
There are also risks to consider. The medical device sector in India faces intense competition from global MNCs that already have strong supply chains and established distribution networks. Furthermore, shifting regulatory norms can create uncertainty, and any new legislation will take time to reflect in company earnings. Investors may track future government notifications, changes to the approval processes, and any specific fiscal incentives that might be announced in the coming quarters to gauge the actual benefit to domestic players.